You are here:   Videos
Register   |  Login

Get Adobe Flash player Install latest flash player if this video gallery doesn't work.
NSCLC and the ARCHER Trial - interview with Michael Boyer, MD, at ASCO 2012
At the American Society of Clinical Oncology (ASCO) 2012, Michael Boyer, MD, Sidney Cancer Center, Australia, discusses lung cancer and the ARCHER trial. Dacomitinib (PF-00299804) is an oral, once-daily, pan-HER inhibitor. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases.
Recent Video
| 
Most Viewed
Tumor Type : Search :